PE20180772A1 - Vectores retrovirales que contienen un promotor de ubiquitina c humana de orientacion inversa - Google Patents
Vectores retrovirales que contienen un promotor de ubiquitina c humana de orientacion inversaInfo
- Publication number
- PE20180772A1 PE20180772A1 PE2018000004A PE2018000004A PE20180772A1 PE 20180772 A1 PE20180772 A1 PE 20180772A1 PE 2018000004 A PE2018000004 A PE 2018000004A PE 2018000004 A PE2018000004 A PE 2018000004A PE 20180772 A1 PE20180772 A1 PE 20180772A1
- Authority
- PE
- Peru
- Prior art keywords
- promoter
- human ubiquitin
- vectors containing
- retroviral vectors
- reverse oriented
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/854—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/40—Vector systems having a special element relevant for transcription being an insulator
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
Abstract
Se refiere a un vector retroviral recombinante donde el vector comprende un promotor de ubiquitina C (UBC) humana enlazado de forma operativa a un transgen donde el promotor y el transgen se encuentran en una orientacion inversa, de forma tal que la direccion de la transcripcion del transgen del promotor se orienta hacia una repeticion terminal larga (LTR) 5' del vector
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562187678P | 2015-07-01 | 2015-07-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20180772A1 true PE20180772A1 (es) | 2018-05-07 |
Family
ID=57608918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2018000004A PE20180772A1 (es) | 2015-07-01 | 2016-06-22 | Vectores retrovirales que contienen un promotor de ubiquitina c humana de orientacion inversa |
Country Status (12)
Country | Link |
---|---|
US (1) | US20180185415A1 (es) |
EP (1) | EP3317416A4 (es) |
JP (1) | JP2018519827A (es) |
KR (1) | KR20180015751A (es) |
CN (1) | CN107949640A (es) |
AU (1) | AU2016285473A1 (es) |
BR (1) | BR112017028607A2 (es) |
CA (1) | CA2990963A1 (es) |
CL (1) | CL2017003476A1 (es) |
MX (1) | MX2017017062A (es) |
PE (1) | PE20180772A1 (es) |
WO (1) | WO2017003792A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
WO2018170239A1 (en) * | 2017-03-15 | 2018-09-20 | The Regents Of The University Of California | Methods of treating lysosomal disorders |
CN109913499A (zh) * | 2017-12-13 | 2019-06-21 | 上海吉凯基因化学技术有限公司 | 一种适用于长链非编码rna构建及表达的整合型慢病毒载体系统及其应用 |
EP3788070A4 (en) * | 2018-04-30 | 2022-03-09 | The Children's Hospital Of Philadelphia | COMPOSITIONS AND METHODS OF HEMOGLOBIN PRODUCTION |
CN108707627A (zh) * | 2018-05-31 | 2018-10-26 | 深圳市免疫基因治疗研究院 | 一种mld慢病毒载体、慢病毒及其制备方法和应用 |
CN108728494A (zh) * | 2018-05-31 | 2018-11-02 | 深圳市免疫基因治疗研究院 | 一种x-scid慢病毒载体、慢病毒及其制备方法和应用 |
CN108728495A (zh) * | 2018-05-31 | 2018-11-02 | 深圳市免疫基因治疗研究院 | 一种Sanfilippo A综合症慢病毒载体、慢病毒及其制备方法和应用 |
US20220136007A1 (en) * | 2019-02-14 | 2022-05-05 | The Regents Of The University Of California | Optimized lentiviral vector compromising minimal enhancer elements for stem cell gene therapy of hemoglobinopathies |
CN112195195A (zh) * | 2020-12-07 | 2021-01-08 | 和元生物技术(上海)股份有限公司 | 慢病毒包装载体与包装方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999035280A1 (en) * | 1998-01-06 | 1999-07-15 | Bavarian Nordic Research Institute A/S | Reconstituting retroviral vector (recon vector) for targeted gene expression |
IL161229A0 (en) * | 2001-10-02 | 2004-09-27 | Inst Clayton De La Rech | Methods and compositions relating to restricted expression lentiviral vectors and their applications. |
US20090217399A1 (en) * | 2006-03-17 | 2009-08-27 | Massachusetts Institute Of Technology | Lentiviral Vectors That Provide Improved Expression And Reduced Variegation After Transgenesis |
EP2895611A4 (en) * | 2012-09-14 | 2016-04-27 | Univ California | LENTIVIRAL VECTORS FOR STEM CELL GENE THERAPY OF SICKEN LEMENIA |
-
2016
- 2016-06-22 US US15/738,545 patent/US20180185415A1/en not_active Abandoned
- 2016-06-22 PE PE2018000004A patent/PE20180772A1/es unknown
- 2016-06-22 CN CN201680042009.6A patent/CN107949640A/zh active Pending
- 2016-06-22 KR KR1020187002662A patent/KR20180015751A/ko unknown
- 2016-06-22 EP EP16818491.9A patent/EP3317416A4/en not_active Withdrawn
- 2016-06-22 WO PCT/US2016/038814 patent/WO2017003792A1/en active Application Filing
- 2016-06-22 AU AU2016285473A patent/AU2016285473A1/en not_active Abandoned
- 2016-06-22 CA CA2990963A patent/CA2990963A1/en not_active Abandoned
- 2016-06-22 BR BR112017028607A patent/BR112017028607A2/pt not_active Application Discontinuation
- 2016-06-22 MX MX2017017062A patent/MX2017017062A/es unknown
- 2016-06-22 JP JP2017567707A patent/JP2018519827A/ja active Pending
-
2017
- 2017-12-29 CL CL2017003476A patent/CL2017003476A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA2990963A1 (en) | 2017-01-05 |
EP3317416A4 (en) | 2018-12-26 |
CL2017003476A1 (es) | 2018-08-31 |
KR20180015751A (ko) | 2018-02-13 |
AU2016285473A1 (en) | 2018-01-18 |
CN107949640A (zh) | 2018-04-20 |
EP3317416A1 (en) | 2018-05-09 |
BR112017028607A2 (pt) | 2018-09-04 |
MX2017017062A (es) | 2018-09-05 |
US20180185415A1 (en) | 2018-07-05 |
JP2018519827A (ja) | 2018-07-26 |
WO2017003792A1 (en) | 2017-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20180772A1 (es) | Vectores retrovirales que contienen un promotor de ubiquitina c humana de orientacion inversa | |
CR20180519A (es) | Neoantígenos y métodos de su uso | |
EP3325633A4 (en) | RECOMBINANT VECTORS COMPRISING A 2A PEPTIDE | |
EP3323009A4 (en) | MANUFACTURE OF REINFORCED SUPERCONDUCTING YARNS | |
DK3548058T3 (da) | Sammensætninger omfattende peptid wkdeagkplvk | |
IL283385A (en) | Different analogs of gip peptide | |
ZA201903112B (en) | Floating point vector comparison instruction with selectable options | |
IL288419A (en) | Recombinant viral herpes vector | |
EP3977739A4 (en) | REORGANIZATION OF MERGER CANDIDATES ACCORDING TO A GLOBAL MOTION VECTOR CROSS-REFERENCE TO RELATED APPLICATIONS | |
GB2523399B (en) | A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence | |
WO2016192819A3 (en) | Modified peptides and their use for treating chronic inflammatory diseases | |
DK3378870T3 (da) | Nyt antimikrobielt peptid og anvendelse deraf | |
AR098615A1 (es) | Péptido para el tratamiento de hipoglicemia severa | |
MY178931A (en) | Polypeptides with permease activity | |
AR098616A1 (es) | Péptido para el tratamiento de hipoglicemia severa | |
DK3429577T3 (da) | N-lipoinaminosyre eller peptid, derivater og anvendelser deraf | |
CL2020001059A1 (es) | Línea de producción modular y proceso para usarla. | |
DK3507300T3 (da) | Sårhelende peptid | |
DK3570678T3 (da) | Casein-glycomakropeptid-(CGMP)-oligomerer | |
MA51261A (fr) | Solubilité du peptide glp -1 | |
ZA201808275B (en) | Glycoprotein with reduced acetylation rate of sialic acid residues | |
TH168268B (th) | ชิ้นส่วนรถเกี่ยวข้าว | |
FR3041928B1 (fr) | Propulseur d'etrave hors-bord | |
WO2014195381A3 (en) | Polypeptides with permease activity | |
GB201700993D0 (en) | Radical improvements of sea transport |